Legacy Medical Device Cybersecurity

    Legacy Medical Device Cybersecurity: Compensating Controls & Risk Reduction for Fielded Devices.

    We reduce cybersecurity risk for devices in the field, without requiring a redesign, a new FDA submission, or taking the device offline. Whether you're the manufacturer responsible for the device or the hospital managing it, the risk is the same, and the approach differs.

    The short answer

    How do you secure legacy medical devices already in the field?

    Legacy devices often run outdated software that can't be easily patched. Securing them starts with an inventory and SBOM, then a threat model and risk assessment of how they're used today. Compensating controls such as network segmentation, hardening, monitoring and clear customer guidance reduce risk without a redesign. Section 524B applies to premarket submissions sent on or after March 29, 2023.

    No Redesign. No New Submission. No Downtime.

    • Compensating controls
    • Network segmentation
    • Section 524B documentation
    • SBOM reconstruction
    • Free 30-min call
    • No obligation
    • Senior expert on the call
    • Fixed-fee quote in 24-hours
    • NDA available on request
    Trusted by leading MedTech manufacturers since 2022 · See client outcomes and awards
    Christian Espinosa, Founder & CEO

    Reviewed by Christian Espinosa, MBA · Founder & CEO

    Last reviewed

    Fixed-fee engagement

    Legacy device protection: deliverables, inputs, and exclusions

    Included work is defined in the signed proposal. These scope options are not automatic inclusions in every engagement.

    Fixed-fee deliverables

    • Current-state cybersecurity assessment, documented risks, and agreed compensating-control recommendations.
    • Segmentation, access/monitoring recommendations, lifecycle planning, and SBOM reconstruction when specifically included.

    Required inputs

    • Fielded device versions, architecture/interfaces, deployment context, known vulnerabilities, available SBOM/firmware evidence, and support constraints.
    • Clinical-use and hazard context, manufacturer and hospital contacts, change restrictions, and authorized assessment access.

    Exclusions and separate work

    • No automatic hardware/software redesign, deployment, or continued-use decision. A review does not establish that no new submission, downtime, or removal from service will be needed. Manufacturer and healthcare teams assess changes and patient risk.
    • General software verification and validation, clinical performance testing, and full QMS implementation or certification are outside Blue Goat's product cybersecurity scope.
    • The manufacturer retains engineering changes, clinical-risk evaluation, risk acceptance, release approval, and regulatory submission decisions. No regulatory outcome is promised.

    Pricing and scope changes

    A written fixed-fee quote after scoping. The proposal names deliverables, versions, assumptions, required inputs, exclusions, and agreed dates. Additional work requires a separately agreed scope change. Missing inputs, access restrictions, manufacturer fixes, and review feedback can affect delivery.

    What an unprotected legacy device costs you

    A fielded device that hasn't been re-evaluated against current FDA guidance carries three concurrent forms of risk, and they compound the longer the device stays in service.

    Regulatory exposure

    Section 524B applies to submissions made after March 29, 2023, but older fielded devices are still covered by the FDA's postmarket cybersecurity guidance, complaint handling, and correction and removal rules. A fielded device with unaddressed vulnerabilities can lead to an inspection finding, a safety communication, or in the worst case a recall. And the next submission for a modified version brings Section 524B into play.

    Patient safety drift

    A legacy device running unpatched software isn't protected by the cybersecurity controls that cleared it. Attack surfaces expand as the threat landscape evolves; the device doesn't evolve with it. The risk profile that was acceptable at clearance no longer reflects reality.

    Commercial fallout

    A coordinated vulnerability disclosure event on a fielded device is public. It damages the brand, triggers regulatory scrutiny, and can force a market withdrawal. Compensating controls put in place before disclosure greatly reduce that exposure.

    Attack surface

    Legacy / installed-base attack surface

    Legacy devices were rarely built with current cybersecurity expectations and often can't be redesigned. The engagement focuses on compensating controls, network isolation, and a postmarket plan that keeps the installed base defensible without a re-clearance.

    1. 01End-of-support OS / RTOS (Win7, XP, RTOS forks)
    2. 02Hard-coded / shared credentials
    3. 03Unsigned firmware update paths
    4. 04Open service / debug ports
    5. 05Hospital-network exposure (VLAN drift)
    6. 06Vendor remote-support tunnels
    7. 07Legacy mobile companions (deprecated APIs)
    8. 08Decommissioning + media sanitization

    Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.

    What's included

    Reviewer-ready deliverables in one engagement

    Every engagement ships with documented artifacts, traceable, complete, and aligned with current guidance.

    • No redesign required - every deliverable below is built to reduce risk on a device already in the field, with no hardware changes, no new FDA submission, and no removal from service.
    • Risk assessment of fielded devices - current-state cybersecurity posture against FDA's 2026 guidance and Section 524B postmarket obligations, with documented findings ready for an inspector.
    • Compensating control design - when the device's cleared software can't be changed, we design the surrounding controls (access, segmentation, monitoring) that bring residual risk into an acceptable range.
    • Network segmentation guidance - practical, hospital-deployable segmentation patterns that isolate legacy devices from the broader clinical network without breaking integrations.
    • Lifecycle extension planning - a documented path that keeps the device commercially viable and audit-defensible until end-of-support, including SBOM reconstruction where the original is missing.
    Notable incidents

    Public postmarket cybersecurity history

    Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about, and what this engagement is built to cover.

    Free tools

    Try the free tool first.

    Pressure-test the work yourself before you scope an engagement. No signup, results are yours to keep.

    All free tools
    Ready to start Legacy Device Protection?

    Legacy Device Protection - scoped, fixed-fee, built for FDA premarket submissions.

    We reduce cybersecurity risk for devices in the field, without requiring a redesign, a new FDA submission, or taking the device offline. Whether you're the manufacturer responsible for the device or the hospital managing it, the risk is the same, and the approach differs.

    FAQ

    Legacy device cybersecurity FAQs

    Cybersecurity alerts and guides

    Goat's Weekly alerts

    Medical device advisories and safety communications, with links to original sources. An alert is a reason to assess applicability, not proof that your device is affected.

    Threat modeling, eSTAR 7.1, and SBOM evidence

    Connect threats to controls and test evidence. Compare the CISA 2026 SBOM fields with the NTIA 2021 baseline the FDA still cites, plus its support fields. Guidance recommendations remain separate from statutory duties.